{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:53:01Z","timestamp":1791895981213,"version":"4.3.4"},"reference-count":162,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ruth L. Kirschstein National Research Service Award","award":["T32 AI007392"],"award-info":[{"award-number":["T32 AI007392"]}]},{"name":"Consortium for HIV\/AIDS Vaccine Development","award":["UM1 AI144371"],"award-info":[{"award-number":["UM1 AI144371"]}]},{"name":"HIV Vaccine and Research Design","award":["5P01 AI110485"],"award-info":[{"award-number":["5P01 AI110485"]}]},{"DOI":"10.13039\/100006967","name":"Duke University Center for AIDS Research","doi-asserted-by":"crossref","award":["5P30 AI064518"],"award-info":[{"award-number":["5P30 AI064518"]}],"id":[{"id":"10.13039\/100006967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clinthera.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:58:47Z","timestamp":1580864327000},"page":"499-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Innovations in HIV-1 Vaccine Design"],"prefix":"10.1016","volume":"42","author":[{"given":"Letitia D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Anthony","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12509","article-title":"Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development","volume":"275","author":"Bonsignori","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02749-06","article-title":"Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors","volume":"81","author":"Dhillon","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fimmu.2014.00170","article-title":"Reconstructing a B-cell clonal lineage. II. Mutation, selection, and affinity maturation","volume":"5","author":"Kepler","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/345622a0","article-title":"Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160","volume":"345","author":"Berman","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"12282","DOI":"10.1073\/pnas.1413559111","article-title":"Vaccines: science, health, longevity, and wealth","volume":"111","author":"Rappuoli","year":"2014","journal-title":"Proc\u00a0Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0264-410X(98)00207-2","article-title":"Edward Jenner's Inquiry; a bicentenary analysis","volume":"17","author":"Baxby","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2020.01.009_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/003693309704200407","article-title":"Edward Jenner and the eradication of smallpox","volume":"42","author":"Willis","year":"1997","journal-title":"Scott Med J"},{"key":"10.1016\/j.clinthera.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1126\/science.283.5400.357","article-title":"Fusion-competent vaccines: broad neutralization of primary isolates of HIV","volume":"283","author":"LaCasse","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.296.5570.1025b","article-title":"Retraction","volume":"296","author":"Nunberg","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJM199501263320405","article-title":"Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection","volume":"332","author":"Kirchhoff","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199906033402203","article-title":"Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort","volume":"340","author":"Learmont","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-114-2-119","article-title":"The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network","volume":"114","author":"Dolin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/314985","article-title":"Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women","volume":"180","author":"Wright","year":"1999","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/319863","article-title":"Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers","volume":"183","author":"Belshe","year":"2001","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib18","first-page":"hky108","article-title":"Fighting an epidemic in political context: thirty-five years of HIV\/AIDS policy making in the United States","author":"Padamsee","year":"2018","journal-title":"Soc Hist Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib20","series-title":"The moon landing of HIV vaccine research: RV144, ten years later [press\u00a0release]","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.009_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrd1359","article-title":"Scientists slam rationale behind largest HIV vaccine trial","volume":"3","author":"Frantz","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2020.01.009_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.305.5681.177b","article-title":"Support for the RV144 HIV vaccine trial","volume":"305","author":"Coalition","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.1094620","article-title":"Public health: a sound rationale needed for phase III HIV-1 vaccine trials","volume":"303","author":"Burton","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.299.5611.1290","article-title":"Public health AIDS vaccine trial produces disappointment and confusion","volume":"299","author":"J","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1126\/science.299.5612.1495","article-title":"HIV\/AIDS. Vaccine results lose significance under scrutiny","volume":"299","author":"Cohen","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib26","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1128\/JVI.00171-06","article-title":"Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239","volume":"80","author":"Wilson","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib27","doi-asserted-by":"crossref","first-page":"12321","DOI":"10.1128\/JVI.79.19.12321-12331.2005","article-title":"Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys","volume":"79","author":"Liang","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib28","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib29","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.01.009_bib30","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20081524","article-title":"Macaques vaccinated with live-attenuated SIV control replication of heterologous virus","volume":"205","author":"Reynolds","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib31","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/00002030-199816000-00007","article-title":"HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons","volume":"12","author":"Bernard","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2020.01.009_bib32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/515659","article-title":"Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection","volume":"178","author":"Pontesilli","year":"1998","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib33","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(07)61702-4","article-title":"STEP study: disappointing, but not a failure","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.01.009_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.vaccine.2010.10.076","article-title":"Once Bitten, Twice Shy\": participant perspectives in the aftermath of an early HIV vaccine trial termination","volume":"29","author":"Newman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2020.01.009_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.clinthera.2020.01.009_bib37","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-cell responses induced by DNA\/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial","volume":"215","author":"Janes","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib38","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"Robb","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib40","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/vaccines2010015","article-title":"Advancing toward HIV-1 vaccine efficacy through the intersections of immune correlates","volume":"2","author":"Tomaras","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clinthera.2020.01.009_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12514","article-title":"Complex immune correlates of protection in HIV-1 vaccine efficacy trials","volume":"275","author":"Tomaras","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2020.01.009_bib43","doi-asserted-by":"crossref","first-page":"310rv317","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu\u00a0Rev Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib47","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib48","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2020.01.009_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.01.009_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib51","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s00705-018-4011-7","article-title":"Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies","volume":"163","author":"Wang","year":"2018","journal-title":"Arch Virol"},{"issue":"2","key":"10.1016\/j.clinthera.2020.01.009_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01492-18","article-title":"Sensitivity to broadly neutralizing antibodies of recently transmitted HIV-1 clade CRF02_AG viruses with a focus on evolution over time","volume":"93","author":"Stefic","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/JVI.02378-14","article-title":"Polyreactivity and autoreactivity among HIV-1 antibodies","volume":"89","author":"Liu","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib54","doi-asserted-by":"crossref","first-page":"46557","DOI":"10.1038\/srep46557","article-title":"Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals","volume":"7","author":"Cheedarla","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209437","article-title":"Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth","volume":"13","author":"Chukwuma","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.01.009_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.1225416","article-title":"Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses","volume":"337","author":"Burton","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib57","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in\u00a0vitro improves protection against lentiviral infection in\u00a0vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib60","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.it.2016.01.007","article-title":"HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies","volume":"37","author":"de Taeye","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.chom.2019.03.002","article-title":"An asymmetric opening of HIV-1 envelope mediates antibody-dependent cellular cytotoxicity","volume":"25","author":"Alsahafi","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.clinthera.2020.01.009_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses","volume":"12","author":"Tay","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"Montefiori","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.clinthera.2020.01.009_bib65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2012.10.004","article-title":"Broadly neutralizing antibodies against HIV-1: templates for a vaccine","volume":"435","author":"van Gils","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2020.01.009_bib67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.01942-15","article-title":"Chemical cross-linking stabilizes native-like HIV-1 envelope glycoprotein trimer antigens","volume":"90","author":"Schiffner","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env","volume":"22","author":"Kwon","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib69","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1016\/j.vaccine.2009.06.037","article-title":"Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1","volume":"27","author":"Kang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2020.01.009_bib70","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1128\/JVI.79.14.8812-8827.2005","article-title":"Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1","volume":"79","author":"Beddows","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2006.10.032","article-title":"A\u00a0comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120","volume":"360","author":"Beddows","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2020.01.009_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A\u00a0next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib73","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1128\/JVI.01222-13","article-title":"Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers","volume":"87","author":"Khayat","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib74","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/JVI.80.2.835-844.2006","article-title":"Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant","volume":"80","author":"Wu","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib75","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41467-019-10262-5","article-title":"Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence","volume":"10","author":"Sliepen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2020.01.009_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005864","article-title":"Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from clades A, B and C","volume":"12","author":"Klasse","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006913","article-title":"Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques","volume":"14","author":"Klasse","year":"2018","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01656-18","article-title":"Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes","volume":"93","author":"Ringe","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib79","doi-asserted-by":"crossref","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib80","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1073\/pnas.1507793112","article-title":"Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens","volume":"112","author":"Julien","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.009_bib81","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.xphs.2019.01.033","article-title":"Developability assessment of physicochemical properties and stability profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 envelope glycoprotein trimers as candidate vaccine antigens","volume":"108","author":"Whitaker","year":"2019","journal-title":"J\u00a0Pharm Sci"},{"issue":"22","key":"10.1016\/j.clinthera.2020.01.009_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00862-17","article-title":"High-throughput protein engineering improves the antigenicity and stability of soluble HIV-1 envelope glycoprotein SOSIP trimers","volume":"91","author":"Sullivan","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib83","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1128\/JVI.03451-14","article-title":"Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 env","volume":"89","author":"Georgiev","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"Sharma","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib85","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3389\/fimmu.2018.01631","article-title":"Structure-guided redesign improves NFL HIV Env trimer integrity and identifies an inter-protomer disulfide permitting post-expression cleavage","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005767","article-title":"Thermostability of well-ordered HIV spikes correlates with the elicitation of autologous tier 2 neutralizing antibodies","volume":"12","author":"Feng","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006614","article-title":"Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response","volume":"13","author":"Dubrovskaya","year":"2017","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib88","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.immuni.2017.04.021","article-title":"Particulate array of well-ordered HIV clade C Env trimers elicits neutralizing antibodies that display a unique V2 cap approach","volume":"46","author":"Martinez-Murillo","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.01.009_bib89","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3389\/fimmu.2018.01116","article-title":"Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust autologous tier 2 neutralizing antibodies","volume":"9","author":"Bale","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib90","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1038\/ncomms12040","article-title":"Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability","volume":"7","author":"Kong","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2020.01.009_bib91","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.celrep.2018.08.051","article-title":"Rational design of DNA-expressed stabilized native-like HIV-1 envelope trimers","volume":"24","author":"Aldon","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12977-015-0210-4","article-title":"Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity","volume":"12","author":"Sliepen","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.clinthera.2020.01.009_bib93","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.celrep.2016.04.078","article-title":"High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells","volume":"15","author":"Ingale","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib94","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV Vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.01.009_bib95","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens","volume":"48","author":"Abbott","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.01.009_bib97","doi-asserted-by":"crossref","first-page":"16527","DOI":"10.1038\/s41598-018-34853-2","article-title":"Enhancing humoral responses against HIV envelope trimers via nanoparticle delivery with stabilized synthetic\u00a0liposomes","volume":"8","author":"Tokatlian","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00443-17","article-title":"Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses","volume":"91","author":"Bale","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib99","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A\u00a0potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib101","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.aah3945","article-title":"Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice","volume":"353","author":"Sok","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib102","article-title":"The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen","volume":"10","author":"Havenar-Daughton","year":"2018","journal-title":"Sci\u00a0Transl Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2018.01.002","article-title":"HIV immunogens: affinity is key","volume":"48","author":"Prabhu","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.01.009_bib104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2020.01.009_bib105","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"Haynes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib106","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.1218256109","article-title":"Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody","volume":"110","author":"Schmidt","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.009_bib107","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.celrep.2017.12.028","article-title":"Vaccine induction of heterologous tier 2 HIV-1 neutralizing antibodies in animal models","volume":"21","author":"Saunders","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2020.01.009_bib108","first-page":"404","article-title":"Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens","volume":"390","author":"Xiao","year":"2009","journal-title":"Biochem Biophys\u00a0Res\u00a0Commun"},{"key":"10.1016\/j.clinthera.2020.01.009_bib109","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature09385","article-title":"Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation","volume":"467","author":"Mouquet","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001028","article-title":"A\u00a0limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals","volume":"6","author":"Walker","year":"2010","journal-title":"Plos Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib111","article-title":"Broadly neutralizing antibody responses in a\u00a0large longitudinal sub-Saharan HIV\u00a0primary infection cohort","volume":"12","author":"Landais","year":"2016","journal-title":"Plos\u00a0Pathog"},{"key":"10.1016\/j.clinthera.2020.01.009_bib112","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1233989","article-title":"Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization","volume":"340","author":"Georgiev","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib113","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines: a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2020.01.009_bib115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","article-title":"Stability of endogenous and added RNA in blood specimens, serum, and plasma","volume":"48","author":"Tsui","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2020.01.009_bib116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biomaterials.2018.12.019","article-title":"Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation","volume":"195","author":"Coolen","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.clinthera.2020.01.009_bib117","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib118","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2020.01.009_bib119","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2020.01.009_bib120","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2020.01.009_bib121","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib122","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.clinthera.2020.01.009_bib124","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.vaccine.2015.03.036","article-title":"Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials","volume":"33","author":"Jin","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2020.01.009_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029231","article-title":"Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and\/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults","volume":"7","author":"Kalams","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.01.009_bib126","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib127","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1128\/JVI.00183-14","article-title":"Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes","volume":"88","author":"Mann","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib128","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00263-17","article-title":"DNA priming increases frequency of T-Cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8(+) T-cell responses by interleukin-12 plasmid DNA","volume":"24","author":"Li","year":"2017","journal-title":"Clin Vaccin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202753","article-title":"Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial","volume":"13","author":"Elizaga","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.01.009_bib130","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-label phase I clinical trial of Ad5-EBOV in Africans in China","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2020.01.009_bib131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0000000000000548","article-title":"Adenovirus vectors as HIV-1 vaccines: where are we? what next?","volume":"29","author":"D'Souza","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2020.01.009_bib132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1874357901610010010","article-title":"Development of an Ad5H3 chimera using the \"antigen capsid-incorporation\" strategy for an alternative vaccination approach","volume":"10","author":"Gu","year":"2016","journal-title":"Open Virol J"},{"key":"10.1016\/j.clinthera.2020.01.009_bib133","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0000000000001224","article-title":"Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140","volume":"30","author":"Emmer","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2020.01.009_bib134","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2020.01.009_bib135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib136","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A\u00a0Novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.clinthera.2020.01.009_bib138","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/505979","article-title":"HIV vaccines: new frontiers in vaccine development","volume":"43","author":"Duerr","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib139","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib141","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib142","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib143","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib144","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm.2108","article-title":"Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys","volume":"16","author":"Santra","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/600891","article-title":"Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments","volume":"200","author":"Hudgens","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.clinthera.2020.01.009_bib146","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1541-0420.2009.01189.x","article-title":"Assessing vaccine effects in repeated low-dose challenge experiments","volume":"65","author":"Hudgens","year":"2009","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2020.01.009_bib147","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2020.01.009_bib148","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib151","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal\u00a0antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib153","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib154","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2020.01.009_bib155","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/JVI.03246-15","article-title":"Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design","volume":"90","author":"Kwon","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib156","first-page":"eaa04235","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2020.01.009_bib157","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1128\/JVI.02097-15","article-title":"Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization","volume":"89","author":"Asokan","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clinthera.2020.01.009_bib158","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2020.01.009_bib159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.009_bib160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2020.01.009_bib161","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.009_bib162","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2017.072","article-title":"Gene therapy with an adeno-associated viral vector expressing human interleukin-2 alters immune system homeostasis in humanized mice","volume":"29","author":"Durost","year":"2018","journal-title":"Hum Gene Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820300448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820300448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:41Z","timestamp":1758963161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820300448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":162,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0149291820300448"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in HIV-1 Vaccine Design","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}